Bionexus Gene Lab (BGLC) closed at $0.73 on November 18, 2026, down 4.2% from the previous close, on volume of 2,013 shares (30-day average 6,855).
Data as of November 18, 2026.
BioNexus Gene Lab Reports Quarterly Filing Delay
TipRanks (Mon, 16-Nov 7:42 PM ET)
BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific
Globe Newswire (Tue, 3-Nov 9:00 AM ET)
BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
Globe Newswire (Fri, 30-Oct 9:00 AM ET)
BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence
Globe Newswire (Wed, 7-Oct 8:30 AM ET)
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
Globe Newswire (Mon, 5-Oct 9:00 AM ET)
Market Chameleon (Thu, 4-Dec 5:11 AM ET)
Market Chameleon (Wed, 12-Nov 3:24 AM ET)
Market Chameleon (Mon, 20-Oct 4:17 AM ET)
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
Bionexus Gene Lab trades on the NASDAQ stock market under the symbol BGLC.
As of November 18, 2026, BGLC stock price declined to $0.73 with 2,013 million shares trading.
BGLC has a market cap of $2.15 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BGLC traded as high as $33.90 and as low as $.66.
BGLC has underperformed the market in the last year with a price return of -84.3% while the SPY ETF gained +10.8%. BGLC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.9% and -22.8%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
BGLC support price is $.71 and resistance is $.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGLC shares will trade within this expected range on the day.